View this email in your browser
CMS Releases Outpatient Payment Rate Information for Pathogen Reduced Apheresis Platelets  |  Cerus Launches Continuing Education Program - Blood Safety Online, Now Available! |  INTERCEPT Blood System Highlighted at the International Society of Blood Transfusion (ISBT) |  Cerus - A Promise to Improve Blood Safety |  Science Section: What We're Reading  |  Calendar of Events
CMS Releases Outpatient Payment Rate Information for Pathogen Reduced Apheresis Platelets, Effective July 1, 2017
The Centers for Medicare & Medicaid Services (CMS) has published payment rate information for new HCPCS code Q9988, to be used in place of HCPCS P9072, effective July 1, 2017, for billing pathogen reduced apheresis platelets transfused in the hospital outpatient setting.  Code and payment rate information is as follows:

Q9988 (Platelets, pheresis, pathogen reduced, each unit): $647.40

Click Here to View Billing Rate Information 
Cerus Launches Continuing Education Program - Blood Safety Online, Now Available!
Safe blood donations are critical to improving patient outcomes. Although transfusion-transmitted infectious risk in blood components has been greatly reduced due to current testing measures, bacterial contamination which can cause sepsis, and emerging pathogens, remain as significant infectious risks. Blood Safety Online provides training modules that will outline how blood safety is changing and the methodologies to identify and mitigate the risks associated with blood products. This on-demand webinar provides:

• P.A.C.E.: Professional Acknowledgment for Continuing Education credits
• CBRN: California Board of Registered Nursing continuing education credits
• AACN CERPs: Continuing Education Recognition Points recognized by the AACN Certification Corporation

Click Here to Sign In
INTERCEPT Blood System Highlighted at the International Society of Blood Transfusion (ISBT)
Cerus announced results of 16 abstracts presenting experiences with the INTERCEPT Blood System for platelets, plasma, and red blood cells during the 27th Regional Congress of the International Society of Blood Transfusion (ISBT) in Copenhagen, Denmark held from June 17 to June 21, 2017. ISBT is one of the premier congresses in blood transfusion science and medicine.

“These studies continue to build the body of evidence demonstrating robust pathogen inactivation performance across the full portfolio of INTERCEPT treated blood components,” noted Dr. Richard Benjamin, Cerus' chief medical officer. “In addition, data presented at ISBT support the European launch of our triple storage container platelet set, showing comparable performance to existing sets while improving economics and operational efficiencies." 

Read the Full Press Release Here
Click Here for a Full List of Abstracts
Cerus - A Promise to Improve Blood Safety
Cerus co-founder and Chief Scientific Officer, Larry Corash and Chief Medical Officer Richard Benjamin, discuss the origins of Cerus and the pursuit of blood safety. Watch to get an inside look at the driving commitment behind the INTERCEPT Pathogen System.

Watch the Video Here
Learn More About the INTERCEPT Blood System Here
Science Section: What We’re Reading

Increased Reported Cases of HCV from 2010 through 2015
Centers for Disease Control and Prevention’s (CDC) National Notifiable Diseases Surveillance System (NNDSS).
Read the CDC Summary Here

South Dakota Reports First Human Case of West Nile Virus in 2017
L. Kightlinger. South Dakota Statue News. 14 June 2017.
Read the Article Here

Calendar of Events

ABC (America's Blood Centers) Summer Meeting
August 1-4, 2017 | Providence, RI
Additional Information

KABB (Kentucky Association of Blood Banks)
August 18, 2017 | Frankfurt, KY
Additional Information

SABM (Society for the Advancement of Blood Management)
September 7-9, 2017 | Portland, OR

Additional Information

NCABB (North Carolina Association of Blood Bankers) 
September 10-12, 2017 | Charlotte, NC  
Additional Information

WABB (Wisconsin Association of Blood Banks)
September 12-13, 2017 | Appleton, WI 
Additional Information

ISABB (Indiana Blood Bank Association)
September 20-21, 2017 | Indianapolis, IN
Additional Information

October 7-10, 2017 | San Diego, CA  
Additional Information

ASA (American Society of Anesthesiologists)
October 21-25, 2017 | Boston, MA  
Additional Information
Data for pathogen reduction of the ZIKA virus by the INTERCEPT Blood System, pathogen reduction system, have not been submitted for FDA review.

There is no pathogen inactivation process that has been shown to eliminate all pathogens. Certain non-enveloped viruses (e.g., HAV, HEV, B19 and poliovirus) and Bacillus cereus spores have demonstrated resistance to the INTERCEPT process.

CONTRAINDICATIONS: Contraindicated for preparation of plasma and platelet components intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens. Contraindicated for preparation of platelet and plasma components intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emission bandwidth <375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen.

WARNINGS and PRECAUTIONS: Only INTERCEPT Processing Sets for platelets and plasma are approved for use with the INTERCEPT Blood System. Use only the INTERCEPT INT100 Illuminator for UVA illumination of amotosalen-treated platelet and plasma components. No other source of UVA light may be used. Please refer to the Operator's Manual for the INT100 Illuminator. Discard any platelet or plasma components not exposed to the complete INT100 illumination process. Tubing components and container ports of the INTERCEPT Blood System contain polyvinyl chloride (PVC). Di(2-ethylhexyl) phthalate (DEHP) is known to be released from PVC medical devices, and increased leaching can occur with extended storage or increased surface area contact. Blood components will be in contact with PVC for a brief period of time (approx. 15 minutes) during processing. The risks associated with DEHP released into the blood components must be weighed against the benefits of therapeutic transfusion.

PLATELETS: INTERCEPT processed platelets may cause the following adverse reaction: Acute Respiratory Distress Syndrome (ARDS). An increased incidence of ARDS was reported in a randomized trial for recipients of INTERCEPT processed platelets, 5/318 (1.6%), compared to recipients of conventional platelet components (0/327). Monitor patients for signs and symptoms of ARDS.

PLASMA: Amotosalen-treated plasma may cause the following adverse reaction: Cardiac Events. In a randomized controlled trial of therapeutic plasma exchange (TPE) for TTP, five patients treated with INTERCEPT Blood System processed plasma and none with conventional plasma had adverse events in the cardiac system organ class (SOC) reported. These events included angina pectoris (n=3), cardiac arrest (n=1), bradycardia (n=1), tachycardia (n=1) and sinus arrhythmia (n=1). None of these events resulted in documented myocardial infarction or death. Monitor patients for signs and symptoms of cardiac events during TPE for TTP.

INTERCEPT Blood System for Red Blood Cells is in development and not available for sale.

Rx only. For full prescribing information, please see package insert.
MKT-EN 00165-24
Copyright © 2017 Cerus Corporation, All rights reserved.
Cerus, INTERCEPT Blood System and INTERCEPT are registered trademarks of Cerus Corporation.

Our mailing address is:
Cerus Corporation
1220 Concord Avenue
Concord, California 94520

Add us to your address book

unsubscribe from this list    update subscription preferences